The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | J | Antiinfectives for systemic use | |
2 | J04 | Antimycobacterials | |
3 | J04A | Drugs for treatment of tuberculosis | |
4 | J04AB | Antibiotics |
Code | Title | |
---|---|---|
J04AB01 | Cycloserine | |
J04AB02 | Rifampicin | |
J04AB03 | Rifamycin | |
J04AB04 | Rifabutin | |
J04AB05 | Rifapentine | |
J04AB06 | ||
J04AB30 | Capreomycin |
Active Ingredient | Description | |
---|---|---|
Capreomycin |
Capreomycin is active against human strains of Mycobacterium tuberculosis. |
|
Cycloserine |
Cycloserine is an analog of the amino acid D-alanine. It interferes with an early step in bacterial cell wall synthesis in the cytoplasm by competitive inhibition of two enzymes, L-alanine racemase, which forms D-alanine from L-alanine, and D-alanylalanine synthetase, which incorporates D-alanine into the pentapeptide necessary for peptidoglycan formation and bacterial cell wall synthesis. |
|
Enviomycin |
|
|
Rifabutin |
Rifabutin is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex. |
|
Rifampicin |
Rifampicin is an active bactericidial antituberculosis drug which is particularly active against the rapidly growing extracellular organisms and also has bactericidial activity intracellularly. Rifampicin inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. |
|
Rifapentine |
Rifapentine, a cyclopentyl rifamycin, is an antimycobacterial agent. Rifapentine inhibits DNA-dependent RNA polymerase in susceptible strains of Mycobacterium tuberculosis but not in mammalian cells. At therapeutic levels, rifapentine exhibits bactericidal activity against both intracellular and extracellular M. tuberculosis organisms. |
Title | Information Source | Document Type | |
---|---|---|---|
CAPREOMYCIN Powder for solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CYCLOSERINE Capsules | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
MYCOBUTIN Capsules | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
PRIFTIN Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
RIFADIN Capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
RIFADIN Solvent | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
RIFAREN Capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
RIFASYNT Hard gelatin capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
RIMACTANE Capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |